Browse the evidence

Increases in inflammatory markers from training do not correlate with any outcome variable.

Training-induced inflammation does not impact performance outcomes.

Recent innovations in obesity diagnosis include bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, alongside emerging biomarkers from 'omics' technologies.

Healthcare practitioners should consider incorporating BIA and DXA scans for more accurate obesity diagnosis.

The pathogenesis of obesity-related glomerulopathy is complex, involving multiple factors.

Recognizing the complexity of ORG can guide more targeted therapeutic approaches.

The internet-based marketing of plant-based formulations for enhancing metabolism has surged.

Practitioners should be aware of the growing trend in plant-based metabolism enhancers in the market.

GIP(1-30)NH2 and GIP(1-42) have similar effects on human pancreatic islets.

Both GIP variants can be expected to have similar effects on insulin and glucagon secretion in pancreatic islets.

The SDOC definition has high discriminatory accuracy for identifying ADL disability.

The SDOC criteria can be effectively used to assess risk of ADL disability in older adults.

The rise of childhood obesity in the United States will soon lead to higher than expected death rates at middle ages and a possible decline in life expectancy by midcentury.

Practitioners should be aware of the long-term implications of childhood obesity on health outcomes.

The most detrimental health and longevity effects of childhood obesity will not be seen for decades.

Awareness of delayed health impacts is crucial for long-term health planning.

Current methods used to forecast life expectancy cannot detect the future effects of childhood obesity.

Practitioners should consider the limitations of current forecasting in health planning.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

18F-FDG PET scanning is the most commonly used imaging modality to detect and quantify human BAT activity in vivo.

Clinicians can utilize 18F-FDG PET for assessing BAT activity in patients.

Tissue concentrations and mRNA expression of GLP-1 and PYY do not differ between individuals with obesity and lean controls.

This indicates that obesity does not alter the local production of GLP-1 and PYY in the gut.

GLP-1 RA therapy was associated with a low rate of major adverse events in LVAD patients.

GLP-1 RA appears to be a safe adjunct therapy for LVAD patients.

GLP-1 RA therapy was not associated with increased incidence of GI cancers.

GLP-1 RAs may be a safer option regarding GI cancer risk for patients with type 2 diabetes.

No significant differences were observed in biliary cancer or hepatocellular carcinoma between GLP-1 RAs and other oral antidiabetic medications.

Clinicians can consider GLP-1 RAs without increased concern for biliary or liver cancer risks.

Both drugs are associated with kidney and thyroid disorders.

Healthcare providers should monitor kidney and thyroid function in patients using these medications.

Natural products from plants are a promising source for new lead structures for drug discovery targeting obesity.

Practitioners may consider exploring natural plant metabolites for obesity treatment.

JMV-449 induced noticeable dose-dependent insulin-releasing actions in BRIN-BD11 beta-cells.

JMV-449 may be a promising agent for enhancing insulin secretion in diabetes treatment.

A new classification of patients with diabetes mellitus into clusters can assess the risk of developing diabetic nephropathy.

Practitioners can use this classification to better assess nephropathy risk in diabetic patients.

Systematic screening for advanced fibrosis related to MASLD is recommended for patients with T2D.

Healthcare professionals should implement systematic screening for liver fibrosis in diabetic patients.

Muscle function indices, including peak isometric maximal voluntary contraction and total distance walked, remained unaltered during the study.

Practitioners can note that short-term inactivity may not affect muscle function in older adults as significantly as metabolic health.

The evidence does not support the supplementation with phosphatidic acid (PA) to increase performance or improve body composition in young or elderly men.

Practitioners should be cautious in recommending PA as an anabolic supplement due to lack of supporting evidence.

Three studies suggested no effect of phosphatidic acid on lean body mass.

The lack of effect on lean body mass suggests PA may not be a viable supplement for muscle gain.

Health care expenditures increased by $80 per month during the 13- to 24-month period, excluding the cost of semaglutide.

Practitioners should consider potential increases in health care costs when prescribing semaglutide.